Monitor upcoming data presentations at EHA (June 11-14) and ASCO (May 29-June 2) for cemsidomide; any positive results could act as catalysts. The revenue decline may cap upside, but the beat and pipeline progress support a neutral-to-positive near-term view.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $3.17entry
- T+1 · 6mo ago +16.09%α +15.51% · $3.68
- T+5 · 6mo ago +1.58%α +1.50% · $3.22
- T+20 · 5mo ago +22.08%α +23.81% · $3.87
- T+60 · 3mo ago +14.83%α +10.44% · $3.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue beat ($6.2M vs $4.4M consensus), but total revenue declined 15% YoY from $7.2M. The company highlighted clinical progress for cemsidomide and a new Roche collaboration, with a cash runway to end of 2028. The mixed earnings beat and pipeline catalysts are offset by the revenue decline.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $6.152 million, down from $7.238 million YoY
- Net loss per share $-0.20, improved from $-0.37 YoY
- Beat consensus EPS ($-0.26) and revenue ($4.4M)
- Cash & equivalents $268.3 million; runway to end of 2028
- Phase 2 MOMENTUM trial enrollment on track; Phase 1b combo trial with elranatamab dosed first patient
- New Roche collaboration for degrader-antibody conjugates with $20M upfront
Financial Impact
Revenue declined 15% YoY to $6.2M; net loss narrowed to $25.1M; EPS beat consensus by 30.8%
Risk Factors
- Clinical trial failure or delays for cemsidomide
- Revenue decline trend may continue as collaboration agreements wind down
- Dilution risk from cash burn and potential future capital raises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292648 |
Track record
19 reports on CCCC
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers